NovoCure GAAP EPS of -$0.33 beats by $0.09, revenue of $167M beats by $8.06M

* NovoCure press release [https://seekingalpha.com/pr/20285935-novocure-reports-third-quarter-2025-financial-results] (NVCR [https://seekingalpha.com/symbol/NVCR]): Q3 GAAP EPS of -$0.33 beats by $0.09.
* Revenue of $167M (+7.7% Y/Y) beats by $8.06M.

MORE ON NOVOCURE

* NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum [https://seekingalpha.com/article/4830711-novocure-buy-rating-as-pipeline-gains-drive-renewed-momentum]
* NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) [https://seekingalpha.com/article/4821763-novocure-limited-nvcr-presents-at-morgan-stanley-23rd-annual-global-healthcare-conference]
* NovoCure Q3 2025 Earnings Preview [https://seekingalpha.com/news/4510305-novocure-q3-2025-earnings-preview]
* ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma [https://seekingalpha.com/news/4489223-immunitybio-rises-data-nk-cell-therapy-device-combo-glioblastoma]
* Seeking Alpha’s Quant Rating on NovoCure [https://seekingalpha.com/symbol/NVCR/ratings/quant-ratings]